MDM4 and sarcoma: In keeping with this hypothesis, amplification and/or overexpression of MDM4 has been documented across a wide spectrum of tumours including cutaneous melanoma (68.5%)4, retinoblastoma (65%)5, head and neck squamous carcinoma (50%)6 , breast (19%)3 and sarcoma (17%)7, 8.